New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.60
5.09
+1.80%
Follow ABBV
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $18.9B covered $13.5B of dividends and buybacks. Cash rose by $5.1B. What is a cash flow statement?
- Free cash flow
- $18.9B 93.9% of operating cash flow
- Returned to shareholders
- $13.5B 71.4% of free cash flow
- Debt, net
- $12.2B borrowed
- Change in cash
- +$5.1B over the period
| Operating cash flow | 20.1 |
|---|---|
| Capital expenditures | −1.2 |
| Free cash flow | 18.9 |
| Acquisitions, net | −13.1 |
| Dividends | −12.1 |
| Buybacks, net | −1.3 |
| Debt raised, net | +12.2 |
| Other | +0.7 |
| Change in cash | 5.1 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $19.0B | $21.2B | $19.5B | $20.1B |
| Capex | −$1.2B | −$1.2B | −$1.3B | −$1.2B |
| Free cash flow | $17.8B | $20.0B | $18.2B | $18.9B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
4,233.00 | 3,641.00 | 6,316.00 | 10,348.00 |
Depreciation & Amortization |
8,986.00 | 8,883.00 | 8,716.00 | 7,667.00 | |
Non Cash Items (Other) |
8,176.00 | 10,446.00 | 8,455.00 | 5,535.00 | |
Accounts Receivable Change |
(1,490.00) | 76.00 | (1,276.00) | (808.00) | |
Change in inventories |
(234.00) | (263.00) | (350.00) | (500.00) | |
Accounts Payable Change |
951.00 | 53.00 | 740.00 | (7.00) | |
Income tax paid |
(762.00) | (1,221.00) | (2,069.00) | (1,357.00) | |
Change in other assets and liabilities |
(830.00) | (391.00) | (1,025.00) | (789.00) | |
Operating Cash Flow |
19,030.00 | 21,224.00 | 19,507.00 | 20,089.00 | |
Capital expenditures |
(1,214.00) | (1,244.00) | (1,297.00) | (1,217.00) | |
Net Aquisitions |
(5,441.00) | (5,169.00) | (5,053.00) | (13,111.00) | |
Long-Term Investments Change (Net) |
80.00 | — | — | — | |
Other investing activities |
(29.00) | (110.00) | (189.00) | 838.00 | |
Investing cash flow |
(6,643.00) | (6,482.00) | (6,498.00) | (13,449.00) | |
Repayment/Issuance of Debt (Net) |
(304.00) | 2,627.00 | 418.00 | 12,176.00 | |
Equity Repurchase (Common, Net) |
(808.00) | (1,336.00) | (1,333.00) | (1,334.00) | |
Dividends Paid (Total) |
(11,657.00) | (11,818.00) | (11,978.00) | (12,138.00) | |
Other financial activities |
45.00 | (20.00) | 2.00 | (185.00) | |
Financing cash flow |
(12,724.00) | (10,547.00) | (12,891.00) | (1,481.00) | |
Exchange Rate Adjustment |
42.00 | 21.00 | (16.00) | (14.00) | |
Change in Cash |
(295.00) | 4,216.00 | 102.00 | 5,145.00 | |
Beginning Cash |
5,524.00 | 5,229.00 | 5,229.00 | 5,229.00 | |
Ending Cash |
5,229.00 | 9,445.00 | 5,331.00 | 10,374.00 | |
Stock Based Compensation |
955.00 | 989.00 | 976.00 | 927.00 | |
Dividends Paid (Common) |
(11,657.00) | (11,818.00) | (11,978.00) | (12,138.00) | |
Assets Liabilities Change (Total) |
(2,365.00) | (1,746.00) | (3,980.00) | (3,461.00) | |
Investments Change (Net) |
80.00 | — | — | — | |
Issuance/Purchase of Shares |
(808.00) | (1,336.00) | (1,333.00) | (1,334.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026